Alnylam Pharmaceuticals, Inc. (ALNY) Financials
ALNY Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 5.6 billion | 4.2 billion |
| March 31, 2026 | 5.1 billion | 4.1 billion |
| Dec. 31, 2025 | 5.0 billion | 4.2 billion |
| Sept. 30, 2025 | 4.9 billion | 4.6 billion |
ALNY Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | 40.6 million | 86.6 million |
| March 31, 2026 | 48.7 million | 70.2 million |
| Dec. 31, 2025 | 140.3 million | 71.6 million |
| Sept. 30, 2025 | 313.0 million | 108.2 million |
ALNY Net Income
No data available :(
ALNY Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 3.3 billion | 1.0 billion | 256.4 million |
| March 31, 2026 | 3.0 billion | 1.0 billion | 263.7 million |
| Dec. 31, 2025 | 2.9 billion | 1.0 billion | 270.6 million |
| Sept. 30, 2025 | 2.7 billion | 1.0 billion | 268.2 million |
ALNY Shares Outstanding
ALNY Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 34.7 million | 413.1 million | 347.9 million | - |
| March 31, 2026 | 21.8 million | 364.9 million | 322.6 million | - |
| Dec. 31, 2025 | 23.3 million | 372.2 million | 325.4 million | - |
| Sept. 30, 2025 | 12.1 million | 358.8 million | 322.1 million | - |
ALNY Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 1.3 billion | 298.3 million |
| March 31, 2026 | 1.2 billion | 211.1 million |
| Dec. 31, 2025 | 1.1 billion | 267.7 million |
| Sept. 30, 2025 | 1.2 billion | 197.2 million |
ALNY Revenue by Segment
Graph available only for paid members. Upgrade to see it.
ALNY
Price: $253.12
52 week price:
Earnings Per Share: 5.72 USD
P/E Ratio: 38.29
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 712302
Ebitda: -143.6 millionMarket Capitalization: 35.6 billion